Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcement of the Company dated 31 May 2021 ("May Announcement") wherein it was announced, among other things, that the Company, the Vendor and GP Corp. entered into the Supplementary Agreement to extend the Option A Exercise Period. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the May Announcement.

It was stated in section 6.3 of the May Announcement that the Circular containing further details of the Supplementary Agreement and other information required under the Listing Rules was expected to be despatched to the Shareholders on or before 30 July 2021.

As additional time is required for the Company to prepare and finalise the financial information, including the statement as to the sufficiency of working capital, the statement as to indebtedness and the accountants' report on the GP Corp Group for inclusion in the Circular, the despatch date of the Circular has been postponed to on or before 24 August 2021.

The Board of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou, the PRC, 30 July 2021

As at the date of this announcement, the Board comprises Mr. Li Chuyuan, Mr. Yang Jun, Ms. Cheng Ning, Ms. Liu Juyan, Mr. Li Hong, Mr. Wu Changhai and Mr. Zhang Chunbo as executive directors, and Mr. Wong Hin Wing, Ms. Wang Weihong, Mr. Chen Yajin, and Mr. Huang Min as independent non-executive directors.